2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

outcomes in patients with metastatic triple-negative breast cancer: High
incidence of central nervous system metastates. Cancer. 2008;113:2638-2645.
22. Isakoff S, Goss P, Mayer E, et al. TBCRC009: A multicenter phase II
study of cisplatin or carboplatin for metastatic triple-negative breast cancer
and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011;29
(suppl; abstr 1025).
23. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus
paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-
2676.
24. Miles D, Chan A, Dirix L, et al. Phase III study of bevacizumab plus
docetaxel compared with placebo plus docetaxel for the first-line treatment of
human epidermal growth factor receptor 2-negative metastatic breast cancer.
J Clin Oncol. 2010;28:3239-3247.
25. O’Shaughnessy J, Osborne C, Pippen J, et al. Iniparib plus chemotherapy
in metastatic triple negative breast cancer. N Engl J Med. 2011;364:205-
214.
26. O’Shaughnessy J, Schwartzberg L, Danso M, et al. A randomized phase
III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin
(G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol.
2011;29:(suppl; Abstr 1007).
27. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study
comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as
first-line therapy of metastatic or locally advanced human epidermal growth
factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol.
2011;29:264-271.
28. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond
progression in human epidermal growth factor receptor 2-positive advanced
breast cancer: A German Breast Group 26/Breast International Group 03-05
study. J Clin Oncol. 2009;27:1999-2006.
29. Geyer C, Forster J, Lindquis TD, et al. Lapatinib plus capecitabine for
HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2744.
30. Blackwell K, Burstein H, Storniolo A, et al. Randomized study of
Lapatinib alone or in combination with trastuzumab in women with ErbB2positive,
trastuzumab-refractory metastatic breast cancer. J Clin Oncol.
2010;28:1124-1130.
31. Lin N, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib
in patients with brain metastases from HER2� breast cancer. Clin Cancer
Res. 2009;15:1452-1459.
32. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast
tumours. Nature. 2000;406:747-752.
33. Metzker M. Sequencing technologies - the next generation. Nat Rev
Genet. 2010;11:31-46.
34. Baselga J, Cortés J, Kim S, et al. Pertuzumab plus trastuzumab plus
docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
35. Pedersen M, et al. Sym004: a novel synergistic anti-epidermal growth
factor receptor amtibody mixture with superior anticancer efficacy. Cancer
Res. 2010;70:588-597.
36. Baselga J, Swain S. Novel anticancer targets: Revisiting ERBB2 and
discovering ERBB3. Nat Rev Cancer. 2009;9:463-475.
37. Engelman JA, et al. MET amplification leads to gefitinib resistance in
lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.
38. Liu L, et al. Synergistic effects of foretinib with HER-targeted agents in
MET and HER1- or HER2-coactivated tumor cells. Mol. Cancer Ther. 2011;
10:518-530.
39. Turner N, Lambros M, Horlings H, et al. Integrative molecular profiling
of triple negative breast cancers identifies amplicon drivers and potential
therapeutic targets. Oncogene. 2010;29:2013-2023.
40. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives
endocrine therapy resistance and is a therapeutic target in breast cancer.
Cancer Res. 2010;70:2085-2094.
38
SLEDGE, CARDOSO, WINER, AND PICCART
41. Andre F, Bachelot T, Campone M, et al. A multicenter, open-label phase
II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and nonamplified
metastatic breast cancer. J Clin Oncol. 2011;29(suppl; abstr 508).
42. Bianchi G, Kocsis J, Dirix L, et al. Patient-Reported Outcomes From a
Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab
Emtansine vs Trastuzumab Plus Docetaxel in Previously Untreated Human
Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Presented at: San Antonio Breast Cancer Symposium; 2011; San Antonio, TX.
43. Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal
Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2012;
366:520-529.
44. Yamnik R, Holz M. mTOR/S6K1 and MAPK/RSK signaling pathways
coordinately regulate estrogen receptor alpha serine 167 phosphorylation.
FEBS Lett. 2010;584:124-128.
45. Hanahan D, Weinberg R. Hallmarks of cancer: The next generation.
Cell. 2011;144:646-674.
46. Finn R, Boer K, Lang I, et al. A randomized phase II study of PD
0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with
letrozole for first-line treatment of patients with postmenopausal, estrogen
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)negative
advanced breast cancer. J Clin Oncol. 2011;29 (suppl; abstr
TPS100).
47. Neckers L, Workman P. Hsp90 Molecular Chaperone Inhibitors: Are
We There Yet? Clin Cancer Res. 2012;16:64-76.
48. Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen
receptor-negative breast cancer. Cancer Cell. 2011;20:119-131.
49. Doane A, Danso M, Lal P, et al. An estrogen-receptor negative breast
cancer subset characterized by a hormonally regulated transcriptional program
and response to androgen. Oncogene. 2006;25:3994-4008.
50. Al-Hajj M, Wicha M, Benito-Hernandez A, et al. Prospective identification
of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A.
2003;100:3983-3988.
51. McDermott S, Wicha M. Targeting breast cancer stem cells. Mol Oncol.
2010;4:404-419.
52. Izrailit J, Reedijk M. Developmental pathways in breast cancer and
breast tumor-initiating cells: Therapeutic Implications. Cancer Lett. 2012;
317:115-126.
53. Stylianou S, Clarke R, Brennan K. Aberrant activation of notch
signaling in human breast cancer. Cancer Res. 2006;66:1517-1525.
54. Kasper M, Jaks V, Fiaschi M, et al. Hedgehog signaling in breast
cancer. Carcinogenesis. 2009;30:903-911.
55. Gupta P, Onder T, Jiang G, et al. Identification of selective inhibitors of
cancer stem cells by high-throughput screening. Cell. 2009;138:645-659.
56. Joyce J, Pollard J. Microenvironmental regulation of metastasis. Nature
Rev Cancer. 2009;9:239-252.
57. Robert N, Diéras V, Glaspy J, et al. RIBBON-1: randomized, doubleblind,
placebo-controlled, phase III trial of chemotherapy with or without
bevacizumab for first-line treatment of human epidermal growth factor
receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin
Oncol. 2011;29:1252-1260.
58. Van der Veldt A, Lubberink M, Bahce I, et al. Rapid Decrease in
Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications
for Scheduling of Anti-Angiogenic Drugs. Cancer Cell. 2012;21:82-91.
59. Ebos J, Lee C, Kerbel RS. Tumor and host-mediated pathways of
resistance and disease progression in response to antiangiogenic therapy.
Clin Cancer Res. 2009;15:5020-5025.
60. Ebos J, Lee C, Christensen J, et al. Multiple circulating proangiogenic
factors induced by sunitinib malate are tumor-independent and correlate with
antitumor efficacy. Proc Natl Acad Sci USA.2007;104:17069-17074.